---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-000635"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:15:50.402914+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical expands OKV-119 collaboration with Okava to include dogs for metabolic health

## Summary
- Collaboration expanded to develop OKV-119 (long-acting GLP-1 implant) for dogs for weight management and diabetes.
- Over 50% of U.S. dogs are overweight or obese; leaner dogs can live more than two years longer.
- OKV-119 leverages NanoPortal technology for six-month+ dosing, mimicking fasting effects to improve insulin sensitivity.
- Financial terms not disclosed; partnership minimizes Vivani's costs/risks with upside via milestone payments and royalties.
- Expands prior 2019 collaboration that focused on developing OKV-119 for cats.

## SEC filing metadata
- accession: 0001753926-25-000635
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000635/0001753926-25-000635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000635/vani-20250412.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-000635
- JSON: https://secwatch.observer/filing/0001753926-25-000635.json
- Plain text: https://secwatch.observer/filing/0001753926-25-000635.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.